U.S. President Donald Trump: Renovation Cost of Lincoln Reflecting Pool Reduced to $2 Million in a Week
U.S. President Donald Trump stated in a public speech that the renovation project for the Lincoln Memorial Reflecting Pool was originally planned to cost $301 million and take three years. However, under the push from Interior Secretary Doug Burgum and his team, it was completed in a week for about $2 million, with even better results.
In the same speech, Trump emphasized his promoted "Most Favored Nation Drug Pricing" policy, claiming that U.S. drug prices have dropped from the highest in the world to the lowest, with reductions of 50% to 80%. English media and policy analysts pointed out that such statements involve the re-evaluation of federal project costs and reforms in drug pricing mechanisms, but the specifics of savings and execution details remain contentious and subject to verification.
Source: Public Information
ABAB AI Insight
This statement's core is not about a single project or drug prices, but about the political rewriting of the "government cost function." By comparing originally high-budget, long-cycle projects with extremely low-cost, short-cycle results, it effectively questions the efficiency and budget rationality of the bureaucratic system. This narrative has long existed in American politics and is essentially a re-contestation of the allocation of public sector resources.
Behind the infrastructure cost controversy is a long-established multi-layered approval, contracting, and compliance system in the U.S. This system enhances safety and transparency but also significantly raises costs and timelines. If political forces attempt to compress this structure, it means a rebalancing between efficiency and institutional constraints, potentially resulting in both lower costs and higher risks.
The "Most Favored Nation" mechanism for drug prices touches upon the global pharmaceutical pricing system. The U.S. has long borne high drug prices, essentially providing a profit source for global innovative drug development. If the U.S. forcibly aligns with lower-priced countries, it will directly compress the global profit space of pharmaceutical companies, thereby affecting R&D investment and innovation incentives, which is a repricing of the global pharmaceutical industry's distribution structure.
Placing these two issues within the same narrative reveals a common logic: directly compressing prices and costs through administrative power, substituting short-term efficiency for long-term institutional balance. This path is politically attractive but will lead to a more complex rebalancing process between capital, innovation, and institutional stability.